Quality standards for immunization

被引:10
作者
Gershon, AA
Gardner, P
Peter, G
Nichols, K
Orenstein, W
机构
[1] SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794
[2] BROWN UNIV,DEPT PEDIAT,PROVIDENCE,RI 02912
[3] VET AFFAIRS MED CTR,DEPT MED,MINNEAPOLIS,MN 55417
[4] CTR DIS CONTROL & PREVENT,ATLANTA,GA
关键词
D O I
10.1086/515544
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This is the third in a series of guidelines commissioned by the Infectious Diseases Society of America through its Practice Guidelines Committee, It is presented as a standard of care rather than a practice guideline because the case for following these recommendations is very strong and it should be followed with rare exceptions. The purpose of this guideline is to provide assistance to clinicians when making decisions on providing immunizations to healthy infants, children, and adults. The document is a summary of guidelines already developed by national organizations. The targeted providers are pediatricians, family practitioners, internists, and other physicians who provide immunizations, The IDSA provided the funding, Panel members represent experts in adult and pediatric infectious diseases. The guidelines are evidence-based. A standard ranking system is used for the strength of the recommendations and the quality of the evidence cited in the literature reviewed, The document has been subjected to external review by peer reviewers as well as by the Practice Guidelines Committee and was approved by the IDSA Council, An executive summary and tables highlight the major recommendations. Indicators For measuring compliance with the standards are included, The guideline will be listed on the IDSA home page at http://www.idsociety.org.
引用
收藏
页码:782 / 786
页数:5
相关论文
共 16 条
[1]  
*AD HOC WORK GROUP, 1993, JAMA-J AM MED ASSOC, V269, P1817
[2]  
*AM AC PED, 1997, REP COMM INF DIS
[3]  
*AM COLL PHYS TASK, 1994, GUID AD IMM
[4]  
[Anonymous], 1996, MMWR Recomm Rep, V45, P1
[5]  
[Anonymous], 1994, MMWR Recomm Rep, V43, P1
[6]  
[Anonymous], 1994, COST BENEFIT ANAL ME
[7]  
*CDC, 1990, MMWR-MORBID MORTAL W, V39, P725
[8]   PNEUMOCOCCAL VACCINE - EFFICACY AND ASSOCIATED COST SAVINGS [J].
GABLE, CB ;
HOLZER, SS ;
ENGELHART, L ;
FRIEDMAN, RB ;
SMELTZ, F ;
SCHROEDER, D ;
BAUM, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (22) :2910-2915
[9]  
HATZIANDREU E, 1994, COST BENEFIT OPV VAC
[10]  
HATZIANDREU EJ, 1994, COST BENEFIT ANAL DI